Results 181 to 190 of about 59,711 (283)

Image quality analysis of ⁴⁴Sc on two preclinical PET scanners: a comparison to ⁶⁸Ga. [PDF]

EJNMMI Phys, 2020
Rosar F, Buchholz HG, Michels S, Hoffmann MA, Piel M, Waldmann CM, Rösch F, Reuss S, Schreckenberger M.   +8 more
europepmc   +1 more source

ZDHHC17‐Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance

Advanced Science, EarlyView.
ZDHHC17 palmitoylates CDK4, which together with TRAF6‐mediated ubiquitination, drives cell cycle progression and immune surveillance, revealing a rational combination of CDK4 inhibitors with immune checkpoint blockers for ZDHHC17‐driven cancers. ABSTRACT Uncontrolled cell cycle progression is a hallmark of cancer, tightly regulated by both intrinsic ...
Zekang Wang, Peipei Song, Xueji Wu, Lei Wang, Wei Xie, Pinning Feng, Chao Cheng, Jianping Guo   +7 more
wiley   +1 more source

Performance evaluation of the ACTIVE 7 MAX benchtop preclinical PET scanner in accordance with the NEMA NU 4-2008 standard. [PDF]

EJNMMI Phys
Wang H, Wang K, Yuan Z, Li C, Liao R, Hou Y, Hua J, Tang Y, Ruan Q, Han D, Jiang J.   +10 more
europepmc   +1 more source

A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts. [PDF]

EJNMMI Res, 2020
Paquette M, Phoenix S, Lawson C, Guérin B, Lecomte R, Tai LH, Turcotte ÉE, Leyton JV.   +7 more
europepmc   +1 more source

Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

Advanced Science, EarlyView.
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia, Hui You, Ke Zhang, Hui Jiang, Hongping Liu, Lianghua Liu, Aijie Zhang, You Zhou   +7 more
wiley   +1 more source

Preclinical PET imaging of the developing fetus during pregnancy: Current state and future potential. [PDF]

J Cereb Blood Flow Metab
Pearson TD, Bricault S, Lin YS, Barusso KE, Bodangi S, Wey HY.   +5 more
europepmc   +1 more source

Preclinical PET Imaging of NTSR-1-Positive Tumors with ⁶⁴Cu- and ⁶⁸Ga-DOTA-Neurotensin Analogs and Therapy with an ²²⁵Ac-DOTA-Neurotensin Analog. [PDF]

Cancer Biother Radiopharm, 2021
Li D, Minnix M, Allen R, Bading J, Chea J, Wong P, Bowles N, Poku E, Shively JE.   +8 more
europepmc   +1 more source

Reprogramming the Immune Landscape of Inflammatory Breast Cancer

Advanced Science, EarlyView.
Inflammatory breast cancer is the most lethal subtype of breast cancer and is characterized by an immunosuppressive tumor microenvironment (TME) driven by a complex network of immune cells and inflammatory cytokines, contributing to its aggressiveness and treatment challenges. Immune checkpoint inhibitors, either alone or in combination, show potential
Verena Martinez‐Rodriguez, Suguru Ogata, Xiaoping Wang, Naoto T. Ueno   +3 more
wiley   +1 more source

Preclinical PET imaging in epileptogenesis: towards identification of biomarkers and therapeutic targets. [PDF]

EJNMMI Res
Hernández-Martín N, Pozo-Cabanell I, Fernández de la Rosa R, García-García L, Gómez-Oliver F, Pozo MÁ, Brackhan M, Bascuñana P.   +7 more
europepmc   +1 more source

Senescent Cell Derived Artificial Vesicle‐Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross‐Presentation Efficacy

Advanced Science, EarlyView.
A senolytic sonovaccine platform (SenoVac) is developed, in which senescent cell‐derived vesicles serve as broad senescent cell antigen reservior. The “2‐step” click chemistry strategy for effective lymph node delivery, and ultrasound‐triggered endosomal escape to boost cross‐presentation, ensures efficient senescent cell clearance and disease ...
Liang Zhang, Yubo Lai, Jia Wang, Lingling Liu, Jieyuan An, Mi Qu, Yuan Liang, Bijun Tan, Guodong Yang, Xuekang Yang, Lijun Yuan   +10 more
wiley   +1 more source